The Israeli startup DermAb.io, founded in 2022, has developed personalized biological therapies for individuals suffering from chronic and autoimmune diseases, utilizing a non-invasive technology that painlessly retrieves biomarkers from the skin's surface. Their patented AI platform enables doctors to immediately prescribe the most effective medication for patients.
"There is a strong link between the skin, the immune system, and the gut, the brain, and even the central nervous system. That’s why skin biomarkers are used in disease management," says Meital Portugal, CTO and co-founder of DermAb.io.
Biomarkers can help assess the severity of a disease and even predict it.
Studies have been conducted, primarily on psoriasis, at Hadassah University Hospital in Jerusalem, Sourasky Medical Center in Tel Aviv, and Emek Medical Center in Afula, showing that several molecules detected in the skin through non-invasive sampling can be correlated with the effectiveness of a biological treatment for the disease.
Psoriasis is a condition where the skin renews itself at an abnormally rapid rate. It is not contagious and progresses in flare-ups, the frequency and intensity of which are unpredictable. Despite treatments, psoriasis remains a disease that, depending on its location and extent, can have aesthetic consequences and negatively impact social and professional life. Although it does not pose serious health risks, psoriasis can have significant psychological and social repercussions.
The AI-powered platform currently boasts an 80% accuracy rate in predicting how a patient will respond to therapy. The startup, based in Haifa, is a portfolio company of the MindUP incubator for early-stage digital health startups.
The startup also participated in the MassChallenge Israel 2024 early-stage acceleration program, a four-month intensive course in Jerusalem that helps entrepreneurs thrive on a global scale.
Caroline Haïat
Comments